5 Pharmaceutical Stocks to Buy Based on Billionaire Ken Griffin’s Portfolio

2. Pfizer Inc. (NYSE:PFE)

Citadel Investment Group’s Stake Value: $228,722,000

Percentage of Citadel Investment Group’s 13F Portfolio: 0.04%

Number of Hedge Fund Holders: 74

Citadel Investment Group owns 5.31 million Pfizer Inc. (NYSE:PFE) shares as of Q3 2021, increasing its stake in the company by 650% in the third quarter, making Pfizer Inc. (NYSE:PFE) one of the best pharmaceutical stocks to buy according to billionaire Ken Griffin. Pfizer Inc. (NYSE:PFE) is an American pharmaceutical and biotechnology company that focuses on internal medicine, immunology, inflammation, oncology, rare diseases, anti infectives, and vaccines. 

The company scored headlines when Pfizer Inc. (NYSE:PFE) vaccine for the COVID-19 was approved as one of the best vaccines by the World Health Organization, with Pfizer Inc. (NYSE:PFE) stating on December 8 that three doses of the current vaccine will offer protection against the COVID-19 Omicron variant. 

Pfizer Inc. (NYSE:PFE) announced Q3 earnings on November 2. EPS in the quarter came in at $1.34, beating estimates by $0.25. The $24.09 billion revenue also outperformed estimates by $1.28 billion, jumping 98.62% year-over-year. 

Ric Dillon’s Diamond Hill Capital is the biggest Pfizer Inc. (NYSE:PFE) stakeholder from Q3, with 10.64 million shares worth $457.89 million. Overall, 74 hedge funds in the database of Insider Monkey were long Pfizer Inc. (NYSE:PFE) in the third quarter, up from 67 funds in the previous quarter. 

Here is what ClearBridge Investments has to say about Pfizer Inc. (NYSE:PFE) in its Q1 2021 investor letter:

“Our underweights in health care and staples contributed to relative performance during the period. As we continue to focus the portfolio on high-conviction ideas, we sold Pfizer in late 2020, in the health care sector.”